216 related articles for article (PubMed ID: 32222072)
1. Integrated omics analysis of sweat reveals an aberrant amino acid metabolism pathway in Vogt-Koyanagi-Harada disease.
Cui X; Su G; Zhang L; Yi S; Cao Q; Zhou C; Kijlstra A; Yang P
Clin Exp Immunol; 2020 Jun; 200(3):250-259. PubMed ID: 32222072
[TBL] [Abstract][Full Text] [Related]
2. Metabolomic Analysis of Aqueous Humor Identifies Aberrant Amino Acid and Fatty Acid Metabolism in Vogt-Koyanagi-Harada and Behcet's Disease.
Xu J; Su G; Huang X; Chang R; Chen Z; Ye Z; Cao Q; Kijlstra A; Yang P
Front Immunol; 2021; 12():587393. PubMed ID: 33732231
[TBL] [Abstract][Full Text] [Related]
3. Plasma metabolomics study of Vogt-Koyanagi-Harada disease identifies potential diagnostic biomarkers.
Chen L; Chang R; Pan S; Xu J; Cao Q; Su G; Zhou C; Kijlstra A; Yang P
Exp Eye Res; 2020 Jul; 196():108070. PubMed ID: 32439397
[TBL] [Abstract][Full Text] [Related]
4. Identification of Urine Metabolic Biomarkers for Vogt-Koyanagi-Harada Disease.
Chang R; Zhu Y; Xu J; Chen L; Su G; Kijlstra A; Yang P
Front Cell Dev Biol; 2021; 9():637489. PubMed ID: 33718374
[TBL] [Abstract][Full Text] [Related]
5. Proteomics Profiling of Plasma Exosomes in VKH Patients.
Zheng H; Yang F; Ea V; Zhou L; Wu L; Zhao G; Shao X; Jiang Y; Huang Y; Li X; Zhang X
Curr Mol Med; 2021; 21(8):675-689. PubMed ID: 32682377
[TBL] [Abstract][Full Text] [Related]
6. MIF gene polymorphisms confer susceptibility to Vogt-Koyanagi-Harada syndrome in a Han Chinese population.
Zhang C; Liu S; Hou S; Lei B; Zheng X; Xiao X; Kijlstra A; Yang P
Invest Ophthalmol Vis Sci; 2013 Nov; 54(12):7734-8. PubMed ID: 24194192
[TBL] [Abstract][Full Text] [Related]
7. Integrated Analysis of Key Pathways and Drug Targets Associated With Vogt-Koyanagi-Harada Disease.
Chen Z; Zhong Z; Zhang W; Su G; Yang P
Front Immunol; 2020; 11():587443. PubMed ID: 33384687
[TBL] [Abstract][Full Text] [Related]
8. Sequence analysis of four vitamin D family genes (VDR, CYP24A1, CYP27B1 and CYP2R1) in Vogt-Koyanagi-Harada (VKH) patients: identification of a potentially pathogenic variant in CYP2R1.
Al-Barry MA; Albalawi AM; Sayf MA; Badawi A; Afzal S; Latif M; Samman MI; Basit S
BMC Ophthalmol; 2016 Oct; 16(1):172. PubMed ID: 27716192
[TBL] [Abstract][Full Text] [Related]
9. Vogt-Koyanagi-Harada disease: inquiry into the genesis of a disease name in the historical context of Switzerland and Japan.
Herbort CP; Mochizuki M
Int Ophthalmol; 2007; 27(2-3):67-79. PubMed ID: 17468832
[TBL] [Abstract][Full Text] [Related]
10. Different MicroRNA profiles in Peripheral Blood mononuclear cells from patients with initial-onset and recurrent vogt-Koyanagi-Harada Disease.
Guo K; Li B; Yang F; Zhang M; Zhao G; Zhang X
Mol Biol Rep; 2022 Dec; 49(12):11421-11431. PubMed ID: 35988105
[TBL] [Abstract][Full Text] [Related]
11. The role of interleukin-1 receptor-associated kinases in Vogt-Koyanagi-Harada disease.
Sun M; Yang P; Du L; Yang Y; Ye J
PLoS One; 2014; 9(4):e93214. PubMed ID: 24690905
[TBL] [Abstract][Full Text] [Related]
12. A variant of CLEC16A gene confers protection for Vogt-Koyanagi-Harada syndrome but not for Behcet's disease in a Chinese Han population.
Li K; Hou S; Qi J; Kijlstra A; Yang P
Exp Eye Res; 2015 Mar; 132():225-30. PubMed ID: 25576669
[TBL] [Abstract][Full Text] [Related]
13. Label-free proteomics reveals decreased expression of CD18 and AKNA in peripheral CD4+ T cells from patients with Vogt-Koyanagi-Harada syndrome.
Mao L; Yang P; Hou S; Li F; Kijlstra A
PLoS One; 2011 Jan; 6(1):e14616. PubMed ID: 21297967
[TBL] [Abstract][Full Text] [Related]
14. A study of KIR genes and HLA-C in Vogt-Koyanagi-Harada disease in Saudi Arabia.
Sheereen A; Gaafar A; Iqneibi A; Eldali A; Tabbara KF; Adra C; Al-Hussein K
Mol Vis; 2011; 17():3523-8. PubMed ID: 22219647
[TBL] [Abstract][Full Text] [Related]
15. Increased Expression of Indoleamine 2,3-Dioxygenase (IDO) in Vogt-Koyanagi-Harada (VKH) Disease May Lead to a Shift of T Cell Responses Toward a Treg Population.
Zhang L; Huang Y; Cui X; Tan X; Zhu Y; Zhou W; Wang C; Yuan G; Cao Q; Su G; Kijlstra A; Yang P
Inflammation; 2020 Oct; 43(5):1780-1788. PubMed ID: 32435912
[TBL] [Abstract][Full Text] [Related]
16. Altered gut microbiome composition in patients with Vogt-Koyanagi-Harada disease.
Ye Z; Wu C; Zhang N; Du L; Cao Q; Huang X; Tang J; Wang Q; Li F; Zhou C; Xu Q; Xiong X; Kijlstra A; Qin N; Yang P
Gut Microbes; 2020 May; 11(3):539-555. PubMed ID: 31928124
[TBL] [Abstract][Full Text] [Related]
17. Increased Expression of IL-23 Receptor (IL-23R) in Vogt-Koyanagi-Harada (VKH) Disease.
Wang C; Wang L; Hu J; Li H; Kijlstra A; Yang P
Curr Eye Res; 2018 Nov; 43(11):1369-1373. PubMed ID: 29877734
[TBL] [Abstract][Full Text] [Related]
18. Seasonal Patterns of Vogt-Koyanagi-Harada Disease.
Amaral C; Rodriguez E; Barquet V; Fantauzzi A; De Jesus Rodriguez E; Ulloa-Padilla JP; Pappaterra-Rodriguez M; Requejo GA; Vila MS; Figueroa R; Fernandez CJ; Almodovar JC; Santos C; Oliver AL
Ocul Immunol Inflamm; 2023 Feb; 31(2):362-366. PubMed ID: 35133938
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Clinical Features and Visual Outcome between Sympathetic Ophthalmia and Vogt-Koyanagi-Harada Disease in Chinese Patients.
Yang P; Liu S; Zhong Z; Du L; Ye Z; Zhou W; Kijlstra A
Ophthalmology; 2019 Sep; 126(9):1297-1305. PubMed ID: 30959067
[TBL] [Abstract][Full Text] [Related]
20. Increased serum level of interleukin-33 in Vogt-Koyanagi-Harada correlates with disease activity.
Qian Y; Yu R; Zhao C; Gao F; Zhang M
Clin Immunol; 2021 Oct; 231():108846. PubMed ID: 34478883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
